Monthly Prescribing Reference3h
Crenessity Approved for Classic Congenital Adrenal Hyperplasia
The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study.
MedPage Today3h
FDA Approves First Drug for Classic Congenital Adrenal Hyperplasia in 70 Years
Crinecerfont is the first new treatment in 70 years for classic CAH and the only one that directly reduces excess ...
FiercePharma6h
Neurocrine's Crenessity ends 70-year drought with FDA nod for rare genetic disease
After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), ...
pharmaphorum6h
FDA clears Neurocrine drug for rare adrenal disorder
The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...
Daily1d
FDA Approves Crinecerfont for classic Congenital Adrenal Hyperplasia
The US Food and Drug Administration has approved Crinecerfont for treatment of classic congenital adrenal hyperplasia, ...
Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules ...